[Magnetic resonance tomography of focal liver and spleen lesions. Experiences using ferrite, a new RES-specific MR contrast medium].
Superparamagnetic iron oxide (ferrite), a novel, reticuloendothelial cell-specific contrast agent used for magnetic resonance imaging (MRI), was evaluated in the detection of liver and spleen tumors in animal models and in phase I and II clinical trials in 33 patients. The initial results obtained in experimental cancer models showed a dramatic improvement in tumor detection. Our first clinical trials confirmed the experimental results and showed that ferrite-enhanced MRI significantly (p less than 0.05) increases the detection of individual lesions. Furthermore, the threshold of detectable tumor size decreased significantly, to 3 mm, when standard MR spin echo imaging techniques were used.
Rummeny
E
E
Department of Radiology, Massachusetts General Hospital, Boston.
Weissleder
R
R
Stark
D D
DD
Elizondo
G
G
Ferrucci
J T
JT
D000818:Animals; D003287:Contrast Media; D005290:Ferric Compounds; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000556:secondary; D008279:Magnetic Resonance Imaging; D051381:Rats; D013160:Splenic Neoplasms / Q000175:diagnosis*
D003287:Contrast Media; D005290:Ferric Compounds; C001215:ferrite
Kernspintomographie fokaler Leber- und Milzläsionen. Erfahrungen mit Ferrit, einem neuen RES-spezifischen MR-Kontrastmittel.